You are here

Stem Cells Buzz

Comment

Discuss

Highlights of current exciting developments, ranging from research papers to court decisions to industry regulations

May 21, 2018

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Past Buzz

May 14,2018 What’s the Stem Cells Buzz this Week? – Pericyte-mediated Cardiovascular Healing, MSC-Derived Microvesicles, Allogeneic Stem Cell Therapy for RDEB, and MSC-aided Islet Transplantation!

 

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond! 

 

Reviewing the Potential for Pericytes in Cardiovascular Healing

Pericytes, the mural cells of blood microvessels, represent a promising therapeutic candidate for non-revascularizable coronary artery disease (CAD) due to their angiogenic capacities and their “robustness” in response to a hypoxic environment. A new STEM CELLS review article from the Paolo Mededdu lab (University of Bristol, UK) now summarizes the rationale behind and the current progress towards pericyte‐based cell therapy. Cathery et al. also consider different sources of pericytes and harvesting pericytes from cardiovascular surgery and go onto discuss preclinical animal models of myocardial ischemia and current practices to upgrade the production protocol for translation to the clinic.

MSC-Derived Microvesicles Stabilize Lung Endothelium

Previous studies from the lab of Jae‐Woo Lee (University of California San Francisco, USA) suggested that mesenchymal stem cell (MSC)-derived microvesicles (MVs) reduced lung inflammation, protein permeability, and pulmonary edema in endotoxin‐induced acute lung injury in mice. In their new study, Hu et al. now demonstrate that MSC-MVs restore protein permeability across injured human lung microvascular endothelial cells (HLMVECs) by increasing Ang1 transcription and secretion into the injured endothelium, which prevents “actin stress fiber” formation. For more on this story, head over to STEM CELLS Translational Medicine.

Allogeneic Stem Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa

Previous studies from the laboratory of Mitchell S. Cairo (New York Medical College, Valhalla, New York, USA) highlighted a role for human cord blood‐derived unrestricted somatic stem cell treatment to promote wound healing and ameliorate the blistering phenotype in a recessive dystrophic epidermolysis bullosa (RDEB) mouse model. In their new study, Liao et al. demonstrate significant therapeutic benefits of human allogeneic placental‐derived stem cell (HPDSC) treatment and establish that HPDSCs migrate to the skin and gastrointestinal tract to significantly improve the adherence of the epidermis to the dermis of the skin. See STEM CELLS Translational Medicine now for more on this exciting new study!

MSCs in Islet Transplantation

We end this week with a Perspective from the laboratory of Peter M. Jones (King's College London, UK), who discuss how factors secreted from mesenchymal stem cells (MSCs) hold the potential to improve islet graft functional survival and transplantation outcomes as a means to cure Type 1 diabetes. Specifically, they report on the potential for the application of cell‐free cocktails of MSC‐derived products to treat islets before transplantation. See STEM CELLS Translational Medicine now for what promises to be a fascinating read.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

May 6,2018 What’s the Stem Cells Buzz this Week? - Inter‐species MSC Incompatibility, Promoting Hippocampal Neurogenesis, HIF‐1α Stability and Chondrogenesis, and p70S6 Kinase-1 in MSCs!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Inter‐species Incompatibilities Limit Mesenchymal Stem Cell Efficacy

Pro-inflammatory stimuli “license” the immunomodulatory abilities of mesenchymal stem cells (MSCs) before they can be employed to treat inflammatory diseases and in transplantation. Interestingly, researchers from the lab of Thomas Ritter (National University of Ireland Galway, Ireland) now report that a rat pro‐inflammatory environment cannot “license” human MSCs, causing a failure of human cells to modulate T‐cell activity in vitro and corneal allograft rejection in vivo. Overall, Lohan et al. highlight the potential for ‘false negative’ results in pre‐clinical experiments utilizing xenogeneic cells. See STEM CELLS now for all the details.

Promoting Hippocampal Neurogenesis and Cognitive Ability of Adult Mice

A new study from the lab of Linyin Feng (University of Chinese Academy of Sciences, Beijing, China) has sought to manipulate neural stem cells (NSCs) and enhance endogenous neurogenesis in the adult. Hui et al. now report that a novel small molecular compound, Yhhu‐3792, expands the NSC pool, promotes adult hippocampal neurogenesis, and elevates the cognitive ability of adult mice. Therefore, the authors suggest that Yhhu‐3792 could represent a novel drug candidate for the treatment of hippocampus associated cognitive dysfunction in aging and neurodegenerative diseases. For more information, see the full paper over at STEM CELLS.

HIF‐1α‐stabilizing agents for MSC Chondrogenesis

Hypoxic regulation controls the chondrogenic differentiation of mesenchymal stem cells (MSCs), and so, researchers from the lab of Eileen Gentleman (King's College London, UK) sought to investigate hypoxia-inducible factor (HIF) stabilizing compounds as a means to enhance cartilage formation. Taheem et al. demonstrate that the 2‐oxoglutarate analog DMOG induces HIF signaling and an articular chondrocyte‐like expression profile in human BM‐MSC when compared to compounds that reduce Fe2+ bioavailability (CoCl2 or DFX). For all the fine print, head over to STEM CELLS now!

p70S6 Kinase-1 in Mesenchymal Stem Cells

New research from the laboratory of Katsuyuki Takeda (National Jewish Health, Denver, Colorado, USA) set out to study the roles of all‐trans retinoic acid (ATRA) or mesenchymal stem cells (MSCs) in lung tissue regeneration in animal models of emphysema. Interestingly, this new study highlights a role for p70S6K1 signaling pathway activation in lung repair by MSCs and, therefore, upregulation of this pathway in MSCs may provide therapeutic benefits in the treatment of damaged lung tissue such as emphysema. For more details, see STEM CELLS Translational Medicine.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

May 1,2018 What’s the Stem Cells Buzz this Week? - Cardiomyocyte Maturation, CPCs and ECM, In Vitro effects on Hematopoietic Cells, and AICLI Stem Cell Trial Results!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Cardiomyocyte Maturation requires TLR3 activated NFκB

A new study from the labs of Conrad P. Hodgkinson and Victor J. Dzau (Duke University, Durham, North California, USA) recently set out to understand the processes leading to the production of cardiomyocytes. Hodgkinson et al. discovered that the maturation of committed precursors into mature cardiomyocytes requires the activity of the TLR3‐NFκB pathway. For more details, make your way over to STEM CELLS now!

CPCs and the Extracellular Matrix

A new Perspective article from Clotilde Castaldo (University of Naples “Federico II”, Naples, Italy) and Isotta Chimenti (“La Sapienza” University of Rome, Italy) asks us to consider the importance of the extracellular matrix (ECM) when proposing novel regenerative therapies for heart failure. To this end, the authors we discuss multiple issues regarding cardiac progenitor cell-based tissue engineering strategies, and, conversely, about the possible antifibrotic mechanisms induced by cell therapy. For more on this fascinating subject, see STEM CELLS Translational Medicine.

In Vitro Biology of Human Hematopoietic Cells

The in vitro expansion of human hematopoietic stem (HSCs) and progenitor (HPCs) cells permits their application in a range of experimental strategies, but at what cost? Researchers from the lab of Hector Mayani (National Medical Center, IMSS, San Pablo Tepetlapa, Coyoacan, Mexico) have now established that in vitro culture promoted significant differences, both in functional and genetic terms, when compared to non-cultured cells. Dircio‐Maldonado et al. discovered that in vitro HSCs displayed a deficient content of long‐term culture‐initiating cells, and a marked differentiation bias toward the myeloid lineage, while both HSCs and HPCs demonstrated a limited expansion potential. For all the fine print, head over to STEM CELLS Translational Medicine now!

A Five-Year Study of PuCeT for AICLI

A new STEM CELLS Translational Medicine study brings us the results of a purified CD34+ cell transplantation (PuCeT) therapy for angiitis‐induced critical limb ischemia (AICLI) patients. The five-year-long trial, carried out by researchers from the lab of Zhihui Dong and Weiguo Fu (Fudan University, Shanghai, China), found long‐term efficacy and durability of autologous transplantation of purified CD34+ cells including achievement of ideal limb salvage, recovery of labor competence, and improved quality of life. Great news!

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

April 23,2018 What’s the Stem Cells Buzz this Week? - Stem Cell Radiation Risk, Olfactory Epithelium Progenitor and Stem Cells, MSCs and Heart Disease, and, EpCAM and Colorectal Cancer!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Reviewing Radiation Risk and Stem Cells

The first of this week’s review articles from the lab of Umberto Galderisi (Campania University, Naples, Italy) discusses the effects of low dose ionizing radiation (LDIR) on the biology of stem cell compartments. Due to their long life, stem cells may suffer from multiple LDIR insults from medical diagnosis and therapy, air travel, illegal IR waste dumpsites, or by occupational exposures in the nuclear and medical sectors, which can combine to the detriment of stem cell function. For what sounds like a riveting read, head over to STEM CELLS now.

Notch Signaling in Olfactory Epithelium Stem and Progenitor Cells

A new study from the labs of Yiqun Yu and Hongmeng Yu (Fudan University, Shanghai, China) sought to uncover the role of Notch signaling in the regulation of olfactory epithelium (OE) progenitor/stem cells. Employing in vivo lineage tracing, Dai et al. discovered two potential roles for Notch signaling: 1) marking globose basal cells (GBCs) localized in the OE to regulate normal cellular turnover, and 2) marking HBCs to reconstruct OE after injury. For all the intricate details, see STEM CELLS now!

Reviewing Mesenchymal Stem Cells and Heart Disease

This week’s second review article from the lab of Kim A. Connelly (University of Toronto, Ontario, Canada) aims to summarize the known mechanisms that contribute to mesenchymal stem cell (MSC)‐based cardiac regeneration. Ward et al. highlight results from molecular and preclinical studies, discuss clinical trial results to date, describe ongoing investigations, and assess novel approaches for the enhancement of MSC based cardiac regeneration, such as genetic modification. To get yourself up to date, head to STEM CELLS Translational Medicine now!

Reviewing the Role of EpCAM in Aggressive Colorectal Cancer

Our final review article, from the labs of Maximilian Boesch (Kantonsspital St. Gallen, Switzerland) and Andreas Seeber (Medical University of Innsbruck, Austria), provides an update on the role of epithelial cell adhesion molecule (EpCAM) in cancer stem cells (CSCs) and the epithelial‐to‐mesenchymal transition (EMT) in colorectal cancer (CRC). Additionally, the authors emphasize the potential predictive selection criteria for novel treatment strategies and refined clinical trial design. See STEM CELLS Translational Medicine now for all the fine print.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

April 19,2018 What’s the Stem Cells Buzz this Week? - HSC Radiation Sensitivity, Combined ALS Treatment, Bipotent Megakaryocytic‐Erythroid Progenitors, and Targeting CD133+ Cells!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Mlh1 Null HSCs Are Not Sensitized to Radiation

Space travel will entail exposure of astronauts to a range of radiation insults that can negatively affect adult stem cell function. Hematopoietic stem cells (HSCs) are highly susceptible to these insults and require functional DNA repair pathways for survival. A new study from the laboratories of Stanton L. Gerson (Case Western Reserve University, Ohio) and Scott M. Welford (University of Miami, Florida, USA) has studied the response of HSCs lacking expression of the Mlh1 protein mismatch repair protein to various forms of radiation. Interestingly, Patel et al. discovered that while cosmic radiation represents a significant risk to the hematopoietic system, there is no dependence on MMR capacity. See STEM CELLS Translational Medicine now for all the details.

Combined Stem Cell and Gene Therapy Treatment for ALS

A new study from the labs of Clive N. Svendsen and Gretchen M. Thomsen (Cedars‐Sinai Medical Center, Los Angeles, California, USA) recently sought to assess a new combination therapy to treat amyotrophic lateral sclerosis (ALS). The authors transplanted human cortical‐derived neural progenitor cells engineered to secrete glial cell line‐derived neurotrophic factor (GDNF) into the cortex of a rat model of ALS, where the cells migrated, matured into astrocytes, and released GDNF. Encouragingly, these actions protected motor neurons, delayed disease pathology, and extended survival of the animals. For all the details on this exciting new combination therapy, head over to STEM CELLS now!

Bipotent Megakaryocytic‐Erythroid Progenitors: Concepts and Controversies

A recent review from Juliana Xavier‐Ferrucio and Diane S. Krause (Yale University, New Haven, CT, USA) focuses on recent advances in the identification and characterization of bipotent megakaryocytic‐erythroid progenitors (MEPs). These cells can produce platelets and red blood cells, and a full understanding of their in vivo derivation and fate decision choices represent critical areas for our understanding of normal blood development and processes underlying cancer. For all the recent studies and an excellent overview of the area, see STEM CELLS now!

Targeting CD133+ Cells in Cancer Therapy

The abrogation of cancer stem cells (CSCs) may provide a means to effectively treat many cancer types; however, we lack a means to specifically target CSCs. Now, a new study from the lab of Faris Farassati (Kansas City Veteran Affairs Medical Center, MO, USA) describes the first mutated version of herpes simplex virus‐1 (HSV‐1) that transcriptionally targets CD133+ cells, a marker for CSCs in many human cancers. Terai et al. demonstrate that treatment with this new virus resulted in a loss of viability and invasiveness of cancer cells and inhibited in vivo tumor growth in various mouse models. For all the fine print, see STEM CELLS now!

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

April 16,2018 What’s the Stem Cells Buzz this Week? - Prostate Progenitor Cell Activity, Healing by iPSC-Derived MSCs, MINDY1 and ESC Self‐Renewal, and Stem Cell Therapy for Corneal Scarring!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Intestinal Healing By iPSC-Derived MSCs

The generation of mesenchymal stem cells (MSCs) from patient-specific induced pluripotent stem cells (iPSCs) may represent a convenient source of autologous cells for therapeutic purposes. To test this approach, researchers from the lab of Steven Dow (Colorado State University, USA) compared iPSC-MSCs with adipose-derived MSCs in a mouse model of intestinal protection. Encouragingly, Soontararak et al. discovered that both MSCs types improved overall intestinal health and healing with equivalent potency and therefore, iPSC-MSCs may represent a new therapy for irritable bowel syndrome and other related diseases/disorders. See STEM CELLS Translational Medicine now for all the fine print.

MAO Loss Impairs Prostate Progenitor Cell Activity

To study the influence of monoamine oxidases (MAOs) during mammalian development, researchers from the laboratory of Boyang Jason Wu (Washington State University, USA) investigated a mouse model lacking both MAO isoforms (A and B). Yin et al. established that MAO loss led to prostate atrophy with reduced prostate basal and stem/progenitor cell activity in adult mice, thereby providing insight into the maintenance of prostate structure and function. Furthermore, the team sees possible implications in their work for the development of new treatments for prostatic hyperplasia and prostate cancer. Read all the details at STEM CELLS now.

MINDY1 and Embryonic Stem Cell Self‐Renewal

Previous publications from the lab of Leah A. Vardy (A*STAR, Singapore) determined the critical nature of the polyamine regulator AMD1 for embryonic stem cell self‐renewal. The team now returns with a new study that highlights the relative importance of MINDY1, a new stem cell regulator that acts downstream of the polyamines. James et al. discovered the requirement for high polyamine levels for ESC self‐renewal and that polyamines function, in part, through the promotion of high MINDY1 levels. For more on MINDY1, head over to STEM CELLS now!

Enhanced Stem Cell Therapy for Corneal Scarring

A new study from the lab of James L. Funderburgh (University of Pittsburgh, Pennsylvania, USA) recently sought to explore the potential for compressed collagen gel (CCG) as a vehicle to deliver corneal stromal stem cells (CSSCs) to suppress corneal stromal scarring in a mouse wound‐healing model and promote regeneration of native transparent tissue. Their new STEM CELLS Translational Medicine study now demonstrates that these gels facilitate handling, storage, and transfer of cells to the eye, and gel‐embedded cells exhibit greater potency for corneal regeneration than stem cells alone.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

April 9,2018 What’s the Stem Cells Buzz this Week? - How Cigarette Smoke affects ASCs, MSC-Cancer Cell Cross-talk, Stem Cell Defect in Transgenic Mice, and Gastric Cancer CSCs!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Cigarette Smoking Weakens ASC Therapeutic Activity

A new study from the labs of Keith L. March and Dmitry O. Traktuev (University of Florida, USA) aimed to discover how cigarette smoking affects the therapeutic activity of adipose stem cells (ASCs). Barwinska et al. determined that cigarette smoking decreases vasculogenic activity and limits the ability of ASCs to improve the recovery of ischemic tissue following systemic infusion. Furthermore, the authors linked this loss in therapeutically relevant functions to the loss of the angiostatic factor Activin A. For all the details, head over to STEM CELLS now!

Cross‐talk of Mesenchymal Stem Cells with Cancer Cells

Cross-talk between cancer cells and stem cells mediated by direct and indirect cellular interactions can lead to cell fusion and the creation of new cancer cell hybrids. A new Review article from the lab of Ralf Hass (Hannover Medical School, Germany) focuses on vesicle‐mediated indirect communication in cancer cell-mesenchymal stem cell (MSC) fusion. For more on this thought-provoking topic, make your way over to STEM CELLS now!

Stem Cell Defect in Transgenic Mice

Transplantation studies often employ transgenic mice line expressing the green fluorescent protein (GFP) under the direction of the human ubiquitin C promoter (UBC‐GFP mice). However, a new study from the laboratory of Emanuel Nečas (Charles University, Prague, Czech Republic) now provides evidence for a specific defect in the hematopoiesis of these model mice that compromises the lymphoid‐primed hematopoietic stem cells in the bone marrow and spleen. For more on this surprising finding, see STEM CELLS ASAP!

PGD2 Controls the Biological Behavior of Gastric Cancer CSCs

While many studies have demonstrated that prostaglandin D2 (PGD2) treatment has an anti-tumor effect on gastric cancer, the mechanisms at play remain shrouded in mystery. Now, researchers from the labs of Wenrong Xu and Hui Qian (Jiangsu University, Zhenjiang, China) report that signaling between PGD2 and its receptor (PTGDR2) restricts self‐renew of gastric cancer CSCs in vitro and suppresses tumorigenesis and metastasis in vivo via the inhibition of STAT3 phosphorylation and nuclear expression. Head over to STEM CELLS for all the fine print on this new study.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

April 5,2018 What’s the Stem Cells Buzz this Week? - NSC-mediated PD Brain Rejuvenation, Kidney Stem Cell Perspective, Hypoxia Mimetic for MSCs, and Engineered Adenosine-releasing Neurons!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Rejuvenation of the Parkinson's Disease Brain by Grafted NSCs

A new study from the labs of Stefano Pluchino (University of Cambridge, UK) and Bianca Marchetti (University of Catania, Italy) sought to test the ability of neural stem cell (NSC) grafts to “rejuvenate” the regions of the brain affected by Parkinson’s disease. L'Episcopo et al. discovered that NSCs restored nigrostriatal functionality and that graft‐derived astrocytes and Wnt/β‐catenin signaling modulated the activity of endogenous astrocytes and the innate immune response. The authors suggest that this STEM CELLS study may have therapeutic implications for dopaminergic (mDA) neurons restoration in aged Parkinson’s disease brain.

Therapeutic Potential of Kidney c-Kit+ Cells

Many studies have proposed c-Kit-positive cells as putative stem cells or precursors within the kidney and a new Perspective article from Erika B. Rangel (Hospital Israelita Albert Einstein, São Paulo, Brazil) provides an excellent overview of the field. For all about their progenitor/stem cell properties, kidney regeneration mechanisms, and possible future studies concerning C-Kit positive cells, see STEM CELLS Translational Medicine now!

Desferrioxamine Treatment as a Hypoxia Mimetic for MSCs

The hypoxic culture of mesenchymal stem cells (MSCs) can be expensive and difficult to perform, and so researchers from the lab of Taro Takami (Yamaguchi University, Japan) set out to determine the effectiveness of desferrioxamine (DFO), a hypoxia‐mimetic reagent, as an alternative strategy. Metabolome analysis by Fujisawa et al. highlighted similar metabolite patterns, except purine, pyrimidine, and TCA cycle related metabolites, in hypoxia-treated and DFO-treated MSCs, suggesting that DFO treatment might represent a potential substitute for hypoxic culturing. See STEM CELLS now for all the details.

Human Neurons with High Adenosine Release

While adenosine treatment can provide neuroprotection as part of treatment strategies for a range of indications, systemic administration causes many unwanted side effects. To solve this problem researchers from the groups of Oliver Brüstle (University of Bonn) and Philipp Koch (University of Heidelberg, Germany) have engineered human embryonic stem cell-derived neuroepithelial stem cell so that their progeny (neurons and astrocytes) overexpress adenosine. Excitingly, the neurons displayed an excitation-mediated release of adenosine, suggesting their potential therapeutic utility for the local “on‐demand” delivery to treat conditions, such as epilepsy. Head over to STEM CELLS Translational Medicine for all the fine print.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

April 2,2018 What’s the Stem Cells Buzz this Week? – Limbal Epithelial Cell Culture, Stem Cell-mediated Tendon Regeneration, Quality-Quantity Stem Cell Culture, and Muscle Stem Cell Regulation via FoxM1!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Amniotic Membrane as a Substrate for Limbal Epithelial Cells

A new review article out of the lab of Amer Sehic (University of Oslo, Norway) discusses the rationale behind employing altered versus unaltered amniotic membrane (AM) as a culture substrate for the ex vivo expansion of the limbal epithelial cells (LECs) used to treat limbal stem cell deficiency (LSCD). Of note, the choice of culture substrate can affect cell phenotype, and Utheim et al. present the case for the use of denuded (i.e., de‐epithelialized) AM or intact AM and the option of crosslinking AM to increase thermal and mechanical stability, optical transparency, and resistance to collagenase digestion. Head over to STEM CELLS Translational Medicine now for what sounds like a highly interesting article.

Guided Stem Cell Fate for Tendon Regeneration

The application of stem cells as a treatment for tendon disorders appears to have a very bright future. A new review article from the lab of Zi Yin (Zhejiang University, China) focuses on the search for bioactive molecules that can potentially induce tenogenesis in adult stem cells. Additionally, Zhang et al. also discuss the molecular regulatory mechanisms of tenogenesis, the various challenges in developing standardized protocols for achieving efficient and reproducible tenogenesis, and future directions for tendon regeneration. See STEM CELLS Translational Medicine now for another excellent review article.

Effect of Quality‐Quantity Culture on Diabetic EPC Function

The low total number and functionality of autologous endothelial progenitor cell (EPC) currently hampers their application in ischemic repair and wound healing in diabetic patients. However, a new approach devised by researchers from the lab of Rica Tanaka (Juntendo University, Tokyo, Japan) may have solved this problem. Tanaka et al. demonstrate that their quality‐quantity culture (QQc) system restored the vasculogenic and wound‐healing efficacy of murine diabetic EPCs following transplantation into a mouse model, suggesting that their approach may significantly improve cell-based treatments for diabetic wounds and other ischemic diseases. For more, see STEM CELLS Translational Medicine now!

FoxM1 Regulation of LncRNAs Enhances the Proliferation and Survival of Muscle Stem Cells

A new research article from the laboratories of Jieping Chen and Yu Hou (Third Military Medical University, Chongqing, China) sought to describe the potential function of the FoxM1 transcription factor in muscle satellite cells (SCs). Previous studies had highlighted a role for FoxM1 in regulating cell proliferation, differentiation, senescence, apoptosis, and tissue homeostasis. The author’s new research suggests that FoxM1 mediates SC proliferation and survival via the regulation of two long noncoding RNAs (lncRNAs): Snhg8 and Gm26917. For more of the details on this novel finding, head on over to STEM CELLS now.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!

March 29,2018 What’s the Stem Cells Buzz this Week? - TNF-mediated Stem Cell Fusion, FSTL3-mediated Endothelial Cell Function and Angiogenesis, Definitive Hematopoiesis in iPSCs, and Islet Protection by BMSCs!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Tumor Necrosis Factor Signaling Contributes to Stem Cell Fusion

The fusion of normal and tumorigenic breast epithelial cells with mesenchymal stem cells (MSCs) can lead to the creation of a new cancer cell type. To unravel the mechanisms controlling this process, researchers from the lab of Ralf Hass (Hannover Medical School, Germany) investigated the potential role of Tumor Necrosis Factor (TNF) and receptor downstream signaling. Melzer et al. report that the tumor-associated pro‐inflammatory cytokine Tumor Necrosis Factor-alpha (TNF‐α) can stimulate the in vitro fusion of MSCs and MCF10A breast epithelial cells, thereby contributing to tumor heterogeneity via new hybrid cell formation exhibiting altered properties. Head over to STEM CELLS now for all the details.

Follistatin‐Like 3 enhances iPSC-derived Endothelial Cell Function and Angiogenesis

Endothelial cells (ECs) derived from induced pluripotent stem cells (iPSCs) may provide for the vast numbers of patient-specific cells required for therapeutic applications. Now, researchers from the laboratory of Andriana Margariti (Queen's University Belfast, UK) report that Follistatin‐Like 3 (FSTL3) expression enhances the functionality and maturity of iPSC-ECs by facilitating β‐catenin nuclear translocation and the inhibition of GSK3β activity and Endothelin‐1 induction. Kelaini et al. hope that FSTL3 overexpression may represent an exciting new means to generate therapeutically-relevant numbers of highly functional cells. Head on over to STEM CELLS now for more on this new study.

Definitive Hematopoiesis in Induced Pluripotent Stem Cells

A new study from the lab of George J. Murphy (Boston University School of Medicine, USA) has recently reported a chemically-defined, serum- and feeder‐free directed differentiation approach to produce hematopoietic stem‐progenitor cells (HSPCs) and adult‐type progeny from induced pluripotent stem cells (iPSCs). Leung et al. also established the stage‐specific roles for Notch and the Aryl Hydrocarbon Receptor (AHR) signaling to hematopoietic progenitor development and the production of downstream definitive, adult‐type erythroblasts. For more details on this promising new advance, see STEM CELLS now!

BMSCs Protect Islets against Endoplasmic Reticulum Stress‐induced Apoptosis

A new study from the labs of Nianqiao Gong and Weijie Zhang (Huazhong University of Science and Technology, Wuhan, China) sought to investigate how bone marrow‐derived mesenchymal stem cells (BMSCs) promote favorable outcomes of islet transplantation. He et al. now report that BMSCs protect grafted islets against endoplasmic reticulum stress (ERS)‐induced apoptosis during early stages after transplantation, a finding that may provide a new arena for development for therapies aiming to improve outcomes of islet transplantation. See STEM CELLS now for all the fine print.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!